News, Publications, and Related Stories
UPI.com -- April 21, 2010 Vitamin K -- found in green leafy vegetables -- may protect against non-Hodgkin lymphoma, U.S. researchers said. View Related 
The New York Times -- April 12, 2010 Myeloma experts issued new treatment guidelines for multiple myeloma. View Related 
Mayo Clinic Health Letter -- April 5, 2010 Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. View Related 
Discovery's Edge -- Mayo Clinic's Research Publication Mayo researchers have developed a novel research tool: The first successful transgenic model for replicating how one of the deadliest cancers impacts humans. View Related 
Discoverys Edge - Mayo Clinic's Research Publication Drs. Keith Stewart and Rafael Fonseca are highlighted. View Related 
U.S. News and World Report -- Dec. 7, 2009 Mayo Clinic endocrinologist Matthew Drake, M.D., Ph.D., presented the findings at the Dec. 5 meeting of the American Society of Hematology. View Related 
Medical Edge Newspaper I have been recently diagnosed with chronic lymphocytic leukemia. I am 55 years old, exercise regularly and feel fine. I have no symptoms. My doctor's approach is to "watch and wait." I am uncomfortable with watchful waiting. Is there more aggressive action that can be taken at this time while it is still early? View Related
Co-Leaders of Two Cancer Center Programs Were Among Those Honored Cancer Center recipients are Charles Loprinzi, M.D., co-leader of the Cancer Prevention and Control Program and Rafael Fonseca, M.D., co-leader of the Hematologic Malignancies Program. View Related 
National Cancer Institute (NCI) Cancer Bulletin -- Oct. 6, 2009 Mayo Clinic's Julian Molina, M.D., Ph.D., was among 11 honored. View Related
Medical Edge Newspaper - - Read Column I was told after my recent annual exam that my platelet count is low. Is this something I should be concerned about? What could be causing this? View Related 
Publication: Mayo Clinic Proceedings -- Aug. 2009 See video interview with S. Vincent Rajkumar, M.D. View Related 
Offering cancer patients in Florida and the Southeast access to investigational therapies through rigorously monitored clinical trials "The cancer field is rapidly moving to use of these new agents as a way to improve upon the success we have seen with more traditional therapies, such as chemotherapy and radiation," says says Michael Menefee, M.D., who heads the Phase I Clinical Trial Program in Oncology at Mayo Clinic, Jacksonville. View Related 
Mayo Clinic Cancer Center receives an additional five years of National Cancer Institute (NCI) funding and re-designation as a comprehensive cancer center. 
Publication: Blood -- June 26, 2009 International Myeloma Working Group recommendations View Related 
Medical Edge Newspaper -- Read Column Can you tell me if there is any cure or even some type of relief for MGUS? View Related
Presented at the annual meeting of the American Association for Cancer Research (AACR). View Related 
Publication: Clinical Cancer Research -- Jan. 1, 2009 Mayo Clinic co-authors: Ayalew Tefferi, M.D. and Animesh Pardanani, M.B.B.S, Ph.D. View Related
Presented at the annual meeting of the American Society of Hematology (ASH). "These are high remission rates, and they happened quickly," says Martha Lacy, M.D., Mayo Clinic hematologist and lead researcher on the study. Also encouraging, says Dr. Lacy, is that treatment did not cause significant side effects in most patients. View Abstract 
Presented at the annual meeting of the American Society of Hematology (ASH). The study focused on the impact of statin use on outcomes of patients with two most common lymphoma types, diffuse large B-cell lymphoma and follicular lymphoma. Examples of commonly used statins in the U.S. include Lipitor, Zocor, Parvachol, Lescol, Mevacor and Crestor. View Abstract
Mayo Clinic Cancer Center researcher, Diane F. Jelinek, Ph.D., a consultant in the Department of Immunology at Mayo Clinic in Rochester, received the Gene and Mary Lou Kurtz Professorship in Multiple Myeloma Research. View Related 
William C. Rupp, M.D., has been appointed CEO for the Florida campus effective Nov. 21, Mayo Clinic announced today. Rupp currently leads quality projects for Luther Midelfort, part of Mayo Health System, as well as Mayo Clinic. 
"We believe this new approach is better for patients because it identifies those who will develop aggressive CLL sooner than later and helps delay need for more toxic treatments," says study lead investigator Clive Zent, M.D., a Mayo hematologist. View Abstract 
In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments. View Related 
Study to be presented at the American Society of Clinical Oncology annual meeting The number of women undergoing mastectomy (total breast removal) for early-stage breast cancer has increased in the last three years at Mayo Clinic in Rochester. The increase follows a steady decline during the prior seven years. View Related 
Patient Story -- Warren Farwell When Warren Farwell learned that he had ocular melanoma, he joined a research trial at Mayo Clinic comparing two treatments for this type of cancer. View Related 
Patient Story -- Wendy Hamilton While hiking on a trip with her daughter, Wendy Hamilton often had to stop and rest. View Related
Patient Story -- Sue Stein Sue Stein believes everything happens for a reason, including her seven year battle with cancer and the stem cell transplant that helped her win. View Related
Agreement strengthens relationship and spawns new scientific collaborations "TGen takes seriously our commitment to work toward helping patients with cancer and other disorders. This announcement is another mechanism allowing TGen and Mayo faculty to work bi-directionally in a more seamless fashion," said Jeffrey Trent, Ph.D., TGen's president and scientific director. View Related 
Study lays foundation for future development of effective treatments "This model helps us understand the genetic properties that lead to multiple myeloma and provides a framework for developing better therapies," said Leif Bergsagel, M.D., a Mayo Clinic physician and lead investigator for the study. "We will now be able to test new treatments on models." View Abstract 
Presented at the American Society of Hematology's 2007 meeting "In this study we were hoping to find that a lower dose of steroids would be just as effective," says Vincent Rajkumar, M.D., Mayo Clinic Cancer Center hematologist and lead investigator of the study. "We were surprised to find that the regimen with high-dose steroids actually was decreasing survival, besides contributing to increased side effects." View Related
Mayo Clinic Cancer Center had researchers from many disciplines presenting more than 60 oral abstracts and dozens of posters, also educational sessions and other special events throughout the 2007 ASCO program, June 1-5. View Related 
The National Institutes of Health chose Mayo Clinic as one of the first 12 institutions to receive Clinical and Translational Science Awards (CTSA) in October 2006. "There are two objects in medical education: to heal the sick and advance the science." - Dr. Charles H. Mayo 
Yuan-Ping Pang, Ph.D. established the Computer-Aided Molecular Design Laboratory (CAMDL) to learn more about how biological systems function and to establish models that could lead to new treatments for infectious diseases and cancer. View Related 
Multiple myeloma is the second most common blood cancer in the United States after lymphoma, yet no new treatments have been developed in a generation. "Our goal is to deliver individualized care based on the latest genomic information and drugs available," Dr. Lief Bergsagel says. "We intend to find ways to offer the right drug to the right patient each time. And we're set to be among the first to make it happen for patients with multiple myeloma." View Related 
Publication: Mayo Clinic Proceedings -- March 2007 The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, beta2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment. View Related
Publication: Mayo Clinic Proceedings -- Dec. 2006 Discontinuation of urine studies and reliance on a diagnostic algorithm using only serum studies (protein electrophoresis, immunofixation, and free light chain quantitation) missed 2 (0.5%) of the 428 monoclonal gammopathies with urinary monoclonal proteins, and these 2 cases required no medical intervention. View Related
Custom-fitting a Drug for a Child with Leukemia Some 20 years ago, Mayo Clinic researcher Richard Weinshilboum, M.D., and colleagues made a groundbreaking discovery: They determined why a dose of a drug that could produce astonishing cures in a lethal childhood cancer sometimes also could produce side effects that killed children. The reason behind this strikingly individual response to a drug was found in the genes. With this profound insight into the role that a patient's genetic make-up plays in how the patient responds to a drug, the new field of pharmacogenomic medicine was born. It continues to grow today—Mayo Clinic research leading the way discovering new treatment applications that range from depression, to breast cancer, to chemical dependency. View Related
Tim Stepanek passed away in January 2006 after a long and heroic battle with amyloidosis and multiple myeloma. His family hopes that Tim's story will inspire others help support research to find new ways to diagnose, treat and prevent amyloidosis. "I think the important thing for me and for them [researchers] was to connect it with a patient. They work very, very hard – way over 40 hours a week. They don't often get the benefit of connecting the practical aspects of what they're doing with the reality of patients' lives. That's the exciting thing." Tim Stepanek View Related 
Publication: Cancer Research -- Oct. 15, 2006 To understand better the underlying mechanisms by which tumor cells are resistant to CTL-mediated apoptosis, Yang et al. used a human model of B-cell non-Hodgkin’s lymphoma (B-cell NHL) to show that intratumoral Treg cells inhibit the proliferation and granule production of activated autologous infiltrating CD8+ T Cells. View Related 
The Clinical Research Training Program provides a formal education in all aspects of clinical research, including grant-writing, legal and ethical issues, statistics, epidemiology and study design and protocols. "I realized how exciting research can be, and how exciting it is to advance the science." Jon Ebbert, M.D. View Related
Publication: Mayo Clinic Proceedings -- Aug. 2006 These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits. View Related 
Publication: Mayo Clinic Proceedings -- Aug. 2006 Our experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with osteonecrosis of the jaw. View Related
In helping young investigators, Mayo Clinic again is connecting all the dots -- leading back to the same point, the same mission, ongoing and yet unchanged for over a century: the needs of the patient come first. New, young investigators are critical to biomedical research. Their fresh ideas, innovativeness, and enthusiasm are necessary for scientific progress. Yet the steps from a junior research position toward a self-sufficient laboratory can be difficult. Mayo Clinic is dedicated to fostering future, investigators. Here we look at two of them and what Mayo is doing to help. View Related 
In scientific literature, epidemiologic studies have linked reduced rates of certain cancers to cultures in Asia where green tea is a popular drink. Legend has it that the Chinese Emperor Shen Nung discovered tea around 2737 B.C.E. He was known as the Divine Healer, and that title is almost all one needs to know about why legends, right or wrong, persist. Green tea has come down through the ages, trailing behind it mythic tales of health benefits from "cheering the heart" to reducing inflammation, from improving bladder function to treating tumors. View Related
While the incidence of most cancers has been declining, that of non-Hodgkin's lymphoma has been on the rise. It is the fifth most common type of cancer diagnosed in the United States, with an estimated 300,000 Americans currently living with the disease. Radio-Immunotherapy Holds Promise for Patients with Lymphoma "I'm sorry, Mrs. Wolter, but your cancer is back." Charlotte Wolter had heard this before. The Glencoe, Minn., resident had endured seven months of chemotherapy. And now, after participating in a clinical trial she had hoped would put her cancer into remission, she was hearing the words again. For Wolter and many other patients battling B-cell non-Hodgkin's lymphoma, chemotherapy and radiation often result in tumors shrinking but recurring in the same or other locations. At the same time, there is no cure for the disease. These patients brave difficult treatment regimens, endure a host of side effects, yet still fail to hear those magic words: you're cancer-free. But now a new drug, known as Zevalin, is giving hope to patients who no longer respond to other treatment options. For patients like Wolter, Zevalin appears to be a wish come true. View Related 
Medical Edge Television Imagine being diagnosed with a disease so rare that some doctors don't even know it exists.
Mayo Clinic’s Molecular Medicine Program has three gene therapy clinical trials open in which the entire preclinical cycle—concept, discovery of agent, vector manufacture, toxicology and efficacy studies, and new drug application—was conducted at Mayo The projects engineered strains of the measles virus, MV-CEA and MV-NIS, which kill multiple cancer cells, and can be monitored easily. The open trials are in ovarian cancer, glioblastoma multiforme (brain cancer), and multiple myeloma. This article discusses the general research and the first trial which opened -- ovarian cancer. The projects are a fine example of a clear translational effort from bedside to bench and back to the bedside. 
Medical Edge Television He's a world-class martial arts champion. But his strength could not fend off a deadly cancer. A cancer that causes debilitating pain. It took some intense detective work by doctors at Mayo Clinic to make the diagnosis and find a treatment that would keep this athlete alive.
Publication: Journal of Clinical Oncology -- June 15, 2004 North Central Cancer Treatment Group with National Cancer Institute of Canada View Related
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
Publication: Blood -- Oct. 1, 2003 View Related
|
LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE
Use of this site signifies your agreement to the terms of use.
© 2012 Mayo Foundation for Medical Education and Research. All rights reserved.
